PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
 
AAPS PharmSciTech. 2004 March; 5(1): 29.
Published online 2009 November 27. doi:  10.1208/pt050106
PMCID: PMC2784857

Comparison of the dissolution of metaxalone tablets (Skelaxin) usingUSP apparatus 2 and 3

Abstract

The purpose of this study was to evaluate the effect of pH on the dissolution behavior of metaxalone in the marketed product Skelaxin tablets. The dissolution was evaluated using United States Pharmacopeia (USP) dissolution Apparatus 2 and 3 at pHs ranging from 1.5 to 7.4 Results from these studies show that the dissolution of this product is pH dependent. At low pH (simulated gastric fluid, pH 1.5), the dissolution of metaxalone from Skelaxin tablets, was less than 10% over 75 minutes; whereas, dissolution at pH 4.5 showed greater than 90% release in the same time period. These results were consistent for both Apparatus 2 and 3. This suggests that Skelaxin Tablets should be considered a delayed release dosage form.

KeyWords: Metaxalone, dissolution, pH dependence, apparatus 3

Full Text

The Full Text of this article is available as a PDF (219K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Bruce RB, Turnbull L, Newman J, Pitts J. Metabolism of metaxalone. J Med Chem. 1966;9(3):286–288. doi: 10.1021/jm00321a004. [PubMed] [Cross Ref]
2. Harden RN, Argoff C. A review of three commonly prescribed skeletal muscle relaxants. J Back Musculoskeletal Rehabil. 2000;15(2–3):63–66. [PubMed]
3. Pfeifer MA, Ross DR, Schrage JP, Gelber DA, Schumer MP, Crain GM, Markwell SS, Jung S. A highly successful and novel model for the treatment of chronic painful diabetic neuropathy. Diabetes Care. 1993;16(8):1103–1115. doi: 10.2337/diacare.16.8.1103. [PubMed] [Cross Ref]
4. Spierings EL. Chronic daily headache: a review. Headache Quarterly. 2000;11(3):181–196.
5. Ward TN. Providing relief from headache: current options for acute and prophylactic treatment. Postgrad Med. 2000;108(3):121–128. doi: 10.3810/pgm.2000.09.1.1209. [PubMed] [Cross Ref]
6. Rxlist 2002. Metaxalone Monograph. Available at: http://www.rxlist.com.Accessed April 2001.
7. Saife M, Shah, J, inventors; Assigned to Elan Pharmaceuticals, Inc, Method for increasing the bioavailability of metaxalone. US patent 6 407 128 B1. June 18, 2002.
8. American Society of Health-System Pharmacists.AHFS Drug Information 2001. Bethesda, MD: American Society of Health-System Phamacists; 2001.

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists